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Introduction – Cancer survivors experience disproportionate prevalence of cognitive 
deficits and higher risk of CVD, due to a combination of shared biological mechanisms and 
anticancer treatment cardiotoxicity. Central artery stiffening, which increases following cancer 
diagnosis, inhibits pulsatile flow damping and potentiates microvascular damage, particularly 
within the cerebral circulation. Associations between central arterial stiffness and the risks of 
incident mild cognitive impairment (MCI), CVD diagnosis, and all-cause mortality have been 
previously established in the general population. However, there is a paucity of evidence on the 
association between arterial stiffness and cognitive decline among cancer survivors.  
Hypothesis – We hypothesized that declines in cognitive function would be associated 
with a higher central arterial stiffness and that cognitive function and central arterial stiffness 
would predict risk of CVD diagnosis and all-cause mortality in a large cohort of diverse cancer 
survivors.  
Methods – We evaluated dementia-free cancer survivors in the Framingham Original and 
Offspring Cohorts (n=277, 80±12.3 years old, 56.7%women, 9.3±8.8 years from first diagnosis) 
with baseline carotid-femoral pulse wave velocity (cfPWV) measurements. During baseline and 
subsequent examinations (mean follow-up 7.7±3.9 years), the Mini-Mental State Examination 
(MMSE; global cognitive function) and neuropsychological exams (NP; executive function, 
learning and memory) were evaluated. Multivariable linear and logistic regression models 
determined the relationship between cfPWV and cognitive decline and MCI. Multivariate Cox 
Regression related cfPWV and cognitive function to the risk of CVD diagnosis and all-cause 
mortality. Multivariate models were adjusted for age, sex, depressive symptoms, and traditional 
CVD risk factors.  
  
Results – Higher cfPWV at baseline was significantly associated with a greater rate of 
decline in global cognitive function (ΔMMSE) (p=0.003). Higher cfPWV was also significantly 
associated with clinically defined MCI, whether denoted by an impaired MMSE (OR(95%CI): 
9.2(2.5-33.5), p=0.001) or NP score (4.3 (1.4-13.0), p=0.009) in univariate logistic models. In 
the final model, there was a 3.4-fold increase in risk of CVD in cancer survivors with high 
cfPWV (HR (95%CI): 3.45 (1.04-11.66), p=0.04). Changes in cognitive function were not 
associated with CVD outcomes.  
Conclusion – Our findings suggest an association between central arterial stiffness, 
future cognitive decline, and an increased risk of CVD in a diverse cohort of cancer survivors. 
Our findings support the potential adverse consequences of a stiffening arterial vasculature 
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Chapter 1 - Introduction 
Over the past 30 years, advancements in cancer detection, treatment, and supportive care 
have reduced the cancer death rate by 31% (56), with approximately 17 million cancer survivors 
alive in the United States as of 2019 (37). Importantly, by 2040 this number is projected to grow 
to 26 million and consist predominantly of survivors who are 65 or older (9). Thus, with the 
number of aged cancer survivors progressing at an unprecedented rate (55), a majority of cancer 
patients are expected to live long enough to develop secondary pathologies. Recent studies 
across a spectrum of cancer types have demonstrated that many patients who survive their cancer 
diagnosis are at a higher risk of both cognitive decline across multiple domains (e.g., executive 
function, learning and memory, attention, and processing speed) (34, 41) as well as 
cardiovascular disease (CVD) manifestation (6, 31) compared to the general population. 
Therefore, for this population, maintaining quality of life years into survivorship is dependent on 
our understanding of risk factors within the pathological continuum of secondary outcomes.  
 
Adverse age-related stiffening of the large central arteries, like that which occurs during 
cancer treatment and into survivorship (10, 12, 19, 47, 57), promotes pressure pulsatility entering 
distal vasculature. In youth, primary pulsatile flow damping occurs in the highly compliant aorta 
whose distensibility and elastic recoil redistribute energy throughout the cardiac cycle. 
Conversely, conduit arteries (e.g. carotid) branching off the aorta are much less compliant, which 
presents an impedance mismatch that reflects the pulse wave and protects downstream 
microvasculature from pulsatile energy. The pulse wave reflection returns to the heart during 
diastole, beneficially raising pressure in the proximal aorta that drives perfusion in coronary 
circulation when its resistance is at its lowest (38, 44). With aging, elastin fragmentation occurs 
2 
in elastic arteries and aortic distensibility moves from highest to lowest in the body causing 
pulsatile damping in the aorta to be inhibited. Thus, the velocity at which pulse waves travel 
down the aorta can increase 2–3-fold (59). This increased pulse wave velocity means reflections 
now return to the heart during systole, compromising coronary perfusion and augmenting 
systolic blood pressure instead of diastolic (38, 44). Critically, flow reaching the peripheral 
conduit arteries now has greater pressure and velocity pulsatility. This, in conjunction with the 
now less profound impedance mismatch, and hence, less pulse wave reflection, results in 
penetration of pulsatile flow into the downstream vasculature (29). This pulse wave propagation 
in distal vasculature potentiates microvascular distress, structural and functional abnormalities, 
and end-organ damage (38).  
 
Importantly, organs such as the brain and kidney that require both high flow and low 
resistance vasculature are more susceptible to end-organ damage as they are not well equipped to 
dampen flow pulsatility (2, 61). With respect to cerebral circulation, these pulsations travel 
through cerebral microvasculature and can be detected on the venous side even prior to loss of 
large central artery compliance (65). In the middle cerebral artery, which is a continuation of the 
internal carotid artery and one of three major arteries perfusing the cerebrum, pulsatility index 
has been demonstrated to be significantly influenced by discordant aortic versus carotid artery 
stiffening, increase with age (29), and be higher in those with Alzheimer’s disease and vascular 
dementia (23, 52). Mechanistically, a chronic increase in pulse pressure can functionally and 
structurally compromise cerebrovascular endothelium, whose crucial roles involve matching 
perfusion to neural activity (i.e., functional hyperemia or neurovascular coupling), and 
modulation of vascular tone in response to mechanical shear stress (13, 14, 24). Cerebral 
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microvascular endothelial damage involves disruption of tight junctions, increased blood brain 
barrier (BBB) permeability, and dysregulation of cerebral blood flow — all of which may lead to 
microhemorrhages, white matter hyperintensities, and silent lunar infarcts, and are associated 
with senescence, inflammation, oxidative stress, cerebral hypoperfusion, and cognitive decline 
(14, 61).  
 
Despite numerous studies demonstrating an association between measures of arterial 
stiffness and cognitive decline in the general population (40, 48, 63, 71), there remains a paucity 
of evidence which demonstrates the relationship between increases in central arterial stiffness 
and cognitive decline during cancer survivorship. Therefore, the primary aim of our study was to 
determine the relationship between carotid-femoral pulse wave velocity, cognitive decline, and 
risk of incident mild cognitive impairment (MCI) determined by Trail Making Test (TMT), 
Paired Associate Learning (PAS), and changes in Mini-Mental State Examination (MMSE) 
scores during cancer survivorship. Because cancer and CVD have common risk factors and a 
shared biology (1, 25, 46), our secondary aim was to characterize the contributions of central 




Chapter 2 - Methods 
 Subjects and Study Design 
The Framingham Heart Study (FHS) is an ongoing, prospective, community-based cohort 
study in Framingham, MA originally aimed at identifying the risk factors that contribute to CVD. 
Through 73 years of recurring examination cycles, the FHS has aided in the investigation and 
identification of CVD risk factors as well as risk factors for dementia and relationships between 
human genotypes and phenotypes. During each examination cycle, participants attend a clinical 
evaluation, which includes a physical examination, laboratory testing, and medical history, with 
additional assessments occurring at some, but not all cycles. Data collection commenced with 
recruitment of the Original cohort in 1948. Subsequently, offspring of the Original cohort and 
their spouses were recruited and a second cohort of participants, the Offspring cohort, was added 
in 1971. To date, the FHS has conducted 32 and 9 examination cycles within the Original and 
Offspring cohorts, respectively.  
 
Examination cycle 26 of the Original cohort and examination cycle 7 of the Offspring 
cohort began in 1999 and 1998, respectively. This examination cycle will be referred to as 
baseline henceforth. At baseline, arterial tonometry and assessments of cognitive function were 
performed. Assessments of cognitive function were repeated in subsequent examination cycles in 
each cohort. Participant outcomes, including cause of death and major medical diagnoses, are 
validated, reviewed, and recorded by Framingham investigators throughout the study. These 
records are current to January 2019 in the Original cohort and October 2019 in the Offspring 
cohort. From these records, we identified CVD diagnoses and all-cause mortality occurring in 
5 
our sample between February 1999 and October 2019. This period lasting 20 years and 8 months 
will be referred to as follow-up. 
 
Figure 2.1. Inclusion of study participants. 
 
Five-hundred and fifty-eight participants attended examination cycle 26 of the Original 
cohort and 3,539 attended examination cycle 7 of the Offspring cohort resulting in a total of 
4,097 participants attending the baseline examination cycle (Figure 2.1). Of these, 307 were 
diagnosed with cancer prior to baseline. This included all primary cancers indicated by self-
report at clinical evaluation, which was confirmed by blind review of pathology and clinical 
records by an FHS physician and a trained staff member or research fellow. We did not make 
exclusions based on cancer type or site, except in the case of metastatic cancers. Participants 
were excluded if they had a stroke prior to baseline testing (n=30), resulting in inclusion of 277 
participants (80 ± 12.3 years old, 56.7% women, 9.3 ± 8.8 years from first diagnosis) for further 
analysis. In the current study, omissions were made from this sample based on the availability of 
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individual measures included in each analysis. Details of the samples included in each analysis 
are described below and in Tables 3.1 and 3.2.  
 
 Assessment of Central Arterial Stiffness 
Carotid-femoral pulse wave velocity (cfPWV) was used as an assessment of arterial 
stiffness. As a measure of arterial stiffness, cfPWV is considered the ‘gold-standard’ (28) and is 
recommended by the American Heart Association (62). The arterial tonometry procedures have 
been previously described (39), but in brief, were performed on femoral and carotid arteries with 
simultaneous ECG following 5 minutes of rest in the supine position. Carotid-femoral transit 
distance was estimated by the difference between body surface measurements from the 
suprasternal notch to the femoral and carotid recording sites and corrected for parallel pulse 
wave transmission around the aortic arch and three branch arteries originating therein. 
Tonometry waveforms were aligned according to the ECG R wave. Carotid-femoral pulse wave 
transit time is the time delay of the foot of the pressure wave at carotid and femoral arteries, 
calculated as [the time between ECG R-wave and pulse wave arrival at the femoral measurement 
site] minus [this time interval for the carotid site]. cfPWV was calculated as the quotient of 
carotid-femoral transit distance divided by pulse wave transit time. Analysis reproducibility of 
cfPWV in the FHS has been assessed through blind reanalysis by a second observer of 50 
randomly sampled participants (correlation coefficient, r=0.972) (39). 
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 Assessment of Cognitive Decline and Incident MCI 
 Mini-Mental State Examination (MMSE) 
The MMSE is regarded as a measure of global cognitive function (18). In this study, 
baseline and follow-up MMSE scores for each participant were selected. On an absolute scale, 
scores on the MMSE range from 0-30 (higher scores indicating better cognitive function), with 
scores adjusted relative to the participant’s maximum possible score according to answered 
questions, per standard procedures. To evaluate cognitive decline, the difference between follow-
up and baseline MMSE scores was divided by the time between tests generating a change per 
year score (ΔMMSEy). Further, identification of MCI was made according to ΔMMSEy -0.5 or 
greater, as previously defined (50). 
 
 Neuropsychological Exams 
Full details of the FHS neuropsychological (NP) exams have previously been described 
(7). In the current study, Paired Associate Learning (PAS) and the Trail Making Test (TMT) 
were selected from the battery of NP exams to assess incident MCI during follow-up. PAS, a 
measure of learning and memory, contains both an immediate (PASI) and delayed (PASD) 
component. PASI and PASD were scored from 0-21 and 0-10, respectively, with the scales 
representing a composite score of the easy and hard component associated with each test, and 
higher composite scores reflecting better memory. The TMT, a measure of executive function, 
contains part A (TMT A) and part B (TMT B). TMT scores reflect the time taken to complete the 
task, with lower scores reflecting better cognitive function. TMT B minus TMT A (TMT B-A) 
was used as a third measure of executive function. Described in the Diagnostic and Statistical 
Manual of Mental Disorders (American Psychiatric Association 2013), 1-2 standard deviations in 
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performance relative to the group mean in one or more cognitive domain can be classified as 
mild impairment. In our analysis, identification of MCI was made according to scoring ≥ 1.5 SD 
worse than the mean of the present cohort on any of these tests. 
 
 Outcome Measures 
The primary outcome measures of this study are all-cause mortality and CVD diagnosis. 
All-cause mortality was confirmed by death certificate. CVD development was constituted by: 
myocardial infarction; angina pectoris; intermittent claudication; congestive heart failure; 
cerebrovascular accident including stroke, transient ischemic attack, atherothrombotic brain 
lesion; or related death in the absence of previous occurrence by any of these diseases. Included 
in these cases are those with a definitive CVD development diagnosis evidenced by medical 
record, clinical evaluation, or autopsy record and validated by Framingham Endpoint Review 
Committee or physician review. Follow-up time for each person was calculated as the number of 
days between their arterial tonometry measurement and outcome or most recent update to the 
FHS outcome file.  
 
 Covariates 
Covariates were assessed at the clinical evaluation during baseline examination. 
Regression models in each analysis were built in a step-wise manner, beginning with a univariate 
model (model 1), while latter models contain the predictors of the predecessor with additions. 
These covariates included age, sex, depressive symptoms (Center for Epidemiologic Studies 
Depression Scale > 16), and time between tonometry and last available exam (model 2); high-
density lipoprotein-cholesterol (HDL), total cholesterol, brachial systolic blood pressure (SBP), 
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brachial diastolic blood pressure (DBP), hypertension medication, statin medication, smoking 
status, and prior CVD diagnosis (model 3).  
 
 Statistical Analysis 
Continuous data are presented as mean ± SD. Categorical data are presented as counts 
and percentages. All analyses were performed using IBM SPSS Statistics for Windows (Ver. 27; 
IBM, Armonk, NY). Linear regression analysis was used to evaluate the relationship between 
cfPWV and cognitive decline (ΔMMSEy). ΔMMSEy was log transformed to improve 
homoscedasticity and kurtosis. Linear analysis of change in NP battery scores was not feasible 
due to unavailable data corresponding to either baseline or follow-up examination in a majority 
of participants. 
 
Logistic regression analyses were done in order to assess likelihoods of incident MCI 
during follow-up in relation to aortic stiffness. MCI defined by either impaired MMSE or NP 
scores, was modeled using cfPWV as a categorical predictor as the assumption of linearity was 
violated. cfPWV was binned into quartiles and analyzed in reference to the lowest quartile 
(cfPWV1).  
 
Cox proportional hazard regression was used to evaluate the risk of CVD diagnosis 
during follow-up using (1) aortic stiffness, (2) cognitive function, and (3) aortic stiffness and 
cognitive function in combination as predictors. In addition, the risk of all-cause mortality during 
follow-up was evaluated in the same manner. Those who had been diagnosed with CVD at 
baseline (n=48) were excluded from these analyses and obesity (BMI ≥ 30) was included as an 
10 
additional covariate to those previously described. Kaplan–Meier plots were used to show the 
difference in time to event by cfPWV quartile and statistically compared with the log-rank test. 
All significance tests were two-sided using p<0.05 as the level of statistical significance. 
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Chapter 3 - Results 
 Baseline Characteristics 
Baseline demographics and subject characteristics are outlined in Table 3.1. A total of 
277 adults (120 men, 157 women) with a history of a cancer diagnosis were included in the 
analysis. In the cancer patients with the highest arterial stiffness (cfPWV4), ΔMMSEy scores 
were significantly greater compared to those of patients within the lowest quartile (cfPWV1) 
(Figure 3.1). Similarly, across cfPWV quartiles, a higher prevalence of MCI occurred in the 
highest cfPWV group compared to cfPWV1 (Table 3.1).  
 
Figure 3.1. A: Patients with the highest central arterial stiffness (cfPWV4) had significantly 
greater rates of cognitive decline compared to reference (cfPWV1). B: Average baseline cfPWV 








Table 3.1. Demographic and clinical characteristics by cfPWV 
 All cfPWV1 cfPWV2 cfPWV3 cfPWV4 
N 277 64 78 49 63 
Age, y 71 ± 12 60 ± 10 67 ± 10* 79 ± 8* 82 ± 7* 
Women, n (%) 157 (56.7%) 40 (62.5%) 42 (53.9%) 26 (53.1%) 36 (57.1%) 
BMI, kg/m2 27.0 ± 4.3 26.3 ± 4.0 26.9 ± 3.7  27.6 ± 4.3 26.6 ± 4.1 
cfPWV, m/s 12.4 ± 5.2 7.5 ± 0.82 10.0 ± 0.81* 13.0 ± 0.81* 19.9 ± 4.4* 
ΔMMSEy -0.17 ± 0.617 -0.052 ± 0.218 -0.053 ± 0.212 -0.22 ± 0.815 -0.45 ± 0.958* 
aMCI defined by MMSE, n (%) 32 (13.8%) 3 (4.8%) 3 (4.1%) 9 (21.4%)* 17 (31.4%)* 
bMCI defined by NP, n (%) 27 (13.6%) 5 (9.3%) 4 (6.8%) 3 (8.1%) 15 (30.6%)* 
Systolic BP, mmHg 127 .1 ± 18.9 116.1 ± 13.4 123.6 ± 14.6* 133.8 ± 17.6* 138.2 ± 21.8* 
Diastolic BP, mmHg 68.7 ± 10.7 66.3 ± 9.8 70.0 ± 11.0 68.6 ± 11.7 70.8 ± 10.1  
Antihypertensive therapy, n 127 (45.8%0 13 (20.3%) 32 (41.0%)* 32 (65.3%)* 40 (63.5%)* 
Statin therapy, n (%) 76 (27.4%) 8 (12.5%) 25 (32.0%)* 13 (26.5%)* 24 (38.1%)* 
Current smoker, n (%) 14 (5.1%) 5 (7.8%) 4 (5.1%) 1 (2.0%) 2 (3.2%) 
Cholesterol, mmol/L 196.7 ± 35.4 194.6 ± 32.2 198.4 ± 34.8 194.1 ± 33.5 195.3 ± 37.1 
HDL cholesterol, mmol/L 55.5 ± 17.7 59.3 ± 16.3 56.9 ± 17.8 54.3 ± 19.6 52.8 ± 15.8 
Cancer Type      
    Breast, n (%) 48 (17.3%) 15 (23.4%) 12 (15.4%) 10 (20.4%) 7 (11.1%) 
    Colon, n (%) 15 (5.4%) 3 (4.7%) 3 (3.8%) 4 (8.1%) 4 (6.3%) 
Time since 1st cancer diagnosis, yr 9.3 ± 8.8 7.9 ± 8.1 8.2 ± 8.6 11.2 ± 10.0* 10.0 ± 8.0 
Multiple cancers, n (%) 151 (54.5%) 31 (48.4%) 49 (62.8%) 27 (55.1%) 31 (49.2%) 
Values are mean ± SD except as noted. 
*Significantly different vs. cfPWV1 (P<0.05). 
aPercentages calculated with respect to participants included in MMSE analysis: Total, n=232; 
cfPWV1, n=63; cfPWV2, n=73; cfPWV3, n=42; cfPWV4, n=54. 
bPercentages calculated with respect to participants included in NP analysis: 
Total, n=199; cfPWV1, n=54; cfPWV2, n=59; cfPWV3 , n=37; cfPWV4, n=49. 
 
 Associations of Central Arterial Stiffness and Cognitive Decline  
Baseline demographics and subject characteristics based on cognitive function are 
outlined in Table 3.2. Over a median follow-up of 11.4 years, we observed 232 cases with an 
average ΔMMSEy of -0.17 ± 0.617, with 32 cases (13.8%) of MCI. In unadjusted linear 
regression analysis, a higher cfPWV was significantly associated with an increased rate of yearly 
decline in global cognitive function (r=0.35, p<0.001) (Figure 3.2). In multivariable-adjusted 
models, aortic stiffness remained significantly associated with ΔMMSEy (model 2: [β±SE] -
0.004±0.55, r=0.39, p=0.002; model 3: -0.004±0.001, r=0.44, p=0.003). Univariate logistic 
regression revealed that compared to the reference cfPWV1, the odds of MCI were 5.5-fold and 
9.2-fold higher for those patients with elevated aortic stiffness in cfPWV3 and cfPWV4 groups, 
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respectively (Table 3.3). However, on multivariate analysis this relationship was no longer 
significant and older age, higher SBP, lower DBP, and lower total cholesterol significantly 
increased the likelihood of incident MCI during survivorship.   
 
Figure 3.2. Significant relationship between higher cfPWV and increased rate of cognitive 
decline shown by univariate linear regression.  
 
Adequate NP battery data was not available for 55 participants, leaving n=199 patients 
for analysis. The unadjusted logistic regression analysis revealed that compared to the reference 
(cfPWV1), the risk of MCI indicated by NP examination scores were 4.3-fold higher for highest 
cfPWV4 group (P=0.009). On multivariate analysis, cfPWV the relationship was inverted with 
higher cfPWV quartiles protective (Table 3.3).  
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Table 3.2. Demographic and clinical characteristics by MCI 
 MMSE normal MMSE impaired P Value NP normal NP impaired P Value 
N 200 32 <0.001 172 27 <0.001 
Age, y 67.4 ± 11.4 84 ± 5.4 <0.001 68.7 ± 11.5 81.5 ± 7.43 <0.001 
Women, n 114 (57.0%) 18 (56.3%) 0.94 102 (59.3%) 14 (51.8%) 0.465 
BMI, kg/m2 27.1 ± 3.9 25.1 ± 4.1 0.018 21.1 ± 4.0 25.9 ± 4.3 0.167 
cfPWV, m/s 11.4 ± 4.5 17.1 ± 6.8 <0.001 11.8 ± 4.9 15.6 ± 6.7 0.009 
Systolic BP, mmHg 125.3 ± 17.5 136.1 ± 22.3 0.012 125.3 ± 17.4 133.7 ± 20.6 0.053 
Diastolic BP, mmHg 69.5 ± 10.3 65.0 ± 10.9 0.033 168.9 ± 10.2 67.1 ± 10.5 0.401 
Antihypertensive therapy, n 84 (42.0%) 21 (65.6%) 0.013 78 (45.3%) 13 (48.1%) 0.786 
Statin therapy, n 53 (26.5%) 11 (34.4%)  0.355 48 (27.9%) 8 (29.6%) 0.853 
Current smoker, n 10 (5.0%) 2 (6.2%) 0.779 7 (4.1%) 1 (3.7%) 0.928 
Cholesterol, mmol/L 198.4 ± 34.1 183.8 ± 34.7 0.032 199.0 ± 34.9 193.5 ± 35.6 0.457 
HDL cholesterol, mmol/L 56.1 ± 17.2 55.8 ± 17.9 0.922 56.4 ± 17.6 55.3 ± 16.6 0.740 
Cancer Type       
    Breast, n 37 (18. 5%) 6 (18.8%) 0.973 32 (18.6%) 6 (22.2%) 0.657 
    Colon, n 10 (5.0%) 3 (9.4%) 0.318 12 (7.0%) 1 (3.7 %) 0.522 
Time since 1st cancer diagnosis, yr 8.5 ± 7.8 13.1 ± 12.6 0.049 8.2 ± 8.2 13.3 ± 11.3 0.033 
Multiple cancers, n 117 (58.5%) 14 (43.8%) 0.118 100 (58.1%) 15 (55.6%) 0.800 
 
 
Table 3.3. Association of cfPWV with Mild Cognitive Impairment on Unadjusted and 
Multivariable-Adjusted Analysis 
  Unadjusted  Multivariable Adjusted* 
Outcome Event rate, n/N (%) OR 95% CI p Value  OR 95% CI p Value 
MMSE         
     cfPWV1 3/73 (4.1%) - - -  - - - 
     cfPWV2 3/63 (4.8%) 0.857 0.167–4.406 0.854  0.344 0.031–3.799 0.384 
     cfPWV3 9/42 (21.4%) 5.455 1.381–21.551 0.016  0.272 0.026–2.848 0.277 
     cfPWV4 17/54 (31.5%) 9.189 2.520–33.514 0.001  0.432 0.040–4.678 0.490 
         
NP         
     cfPWV1 4/59 (6.8%) - - -  - - - 
     cfPWV2 3/37 (8.1%) 0.713 0.181–2.805 0.628  0.224 0.038–1.326 0.099 
     cfPWV3 5/54 (17.4%) 0.865 0.194–3.863 0.849  0.034 0.004–0.321 0.003 
     cfPWV4 15/49 (30.6%) 4.324 1.435–13.023 0.009  0.117 0.015–0.909 0.040 
*Multivariable model adjusted for age, sex, depressive symptoms, and HDL cholesterol, total cholesterol, systolic blood pressure, diastolic 
blood pressure, hypertension medication, statin medication, smoking status, and prior CVD diagnosis.  
MMSE, Mini-Mental State Examination; NP, Neuropsychological examination; cfPWV, carotid-femoral pulse wave velocity.   
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 Associations of Central Arterial Stiffness, Cognitive Impairment, and CVD 
Diagnosis 
 Arterial Stiffness 
In all models arterial stiffness was significantly associated with the risk of CVD 
diagnosis during follow-up. Univariate Cox regression analysis revealed significant associations 
between each cfPWV quartile and risk of CVD diagnosis during follow-up and suggested that, 
compared to the reference cfPWV1, patients with higher cfPWV had 4.5-fold, 9.0-fold, and 10.3-
fold greater risk, with risks corresponding to cfPWV2 (p=0.002), cfPWV3 (p<0.001), and 
cfPWV4 (p<0.001), respectively (Figure 3.3). After controlling for age, sex, and depression 
symptoms, model 2 revealed significant associations between the upper three cfPWV quartiles 
and suggested that patients in cfPWV2, cfPWV3, and cfPWV4 had 3–4-fold greater risk of CVD 
diagnosis compared to cfPWV1. Similar to model 2, full multivariate analysis revealed 
significant associations between the upper three cfPWV quartiles and suggested 3.3–3.5-fold 
greater CVD diagnosis risk for patients with higher cfPWV. Compared to the reference cfPWV1, 
model 2 suggested patients in cfPWV3 had a 3.8-fold greater risk of CVD diagnosis (p=0.017), 
while risk increased 3.6-fold in cfPWV4 (p=0.032). Similarly, the fully adjusted model 3 
indicated that risk increased 3.5-fold for patients in cfPWV2  (p=0.017) and cfPWV4 (p=0.044) 
alike, while risk increased  3.3-fold in cfPWV3 (p=0.038). 
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Figure 3.3. Kaplan-Meier curve analysis of CVD diagnosis across cfPWV quartile. 
 
 Cognitive Impairment 
Univariate Cox regression analysis revealed a significant association between MCI and 
the risk of CVD diagnosis during follow-up, suggesting cognitively impaired patients had a 2.8-
fold greater risk of CVD diagnosis compared to unimpaired patients. However, on multivariate 




In all models using arterial stiffness and cognitive impairment in tandem as predictors, 
arterial stiffness was significantly associated with the risk of CVD diagnosis during follow-up, 
with MCI not significant. Model 1 revealed significant associations between each cfPWV 
quartile and risk of CVD diagnosis during follow-up and suggested that, compared to the 
reference cfPWV1, patients with higher cfPWV had 4.3, 8.5-, and 9.3-fold greater risk, with risks 
corresponding to cfPWV2, cfPWV3, and cfPWV4, respectively. Similar to the cfPWV 
multivariate Cox regression analysis, models 2 and 3 revealed significant associations between 
the upper 3 cfPWV quartiles and CVD diagnosis risk. Both models suggested patients with 
elevated aortic stiffness had a greater risk of CVD diagnosis and that the greatest risk was to 
those in cfPWV4, whose risk increased 3.7-fold from reference cfPWV1. 
 
 Associations of Central Arterial Stiffness, Cognitive Impairment, and All-
Cause Mortality  
 Arterial Stiffness 
Aortic stiffness was not significantly associated with the risk of all-cause mortality in 
univariate or multivariate analysis. The only model as a whole to reach statistical significance 
was the full multivariate model, which suggested patients who were male, had higher SBP, had 
higher total cholesterol, and who smoked had an increased risk of all-cause mortality.    
 
 Cognitive Impairment 
Cognitive impairment was not significantly associated with the risk of all-cause mortality 
in univariate or multivariate analysis. The only model as a whole to achieve statistical 
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significance was the full multivariate model, which suggested patients who were male, had 
higher SBP, had higher total cholesterol, and who smoked had an increased risk of all-cause 
mortality.    
 
 Combined 
In all models using arterial stiffness and cognitive impairment in tandem as predictors, 
aortic stiffness and cognitive impairment were not significantly associated with the risk of all-
cause mortality. The only model as a whole to gain significance was the full multivariate model, 
which suggested patients with higher SBP, higher total cholesterol, who do not take hypertension 





Chapter 4 - Discussion 
We present longitudinal analyses of cancer survivors in the Framingham Heart Study 
unburdened by dementia or stroke which demonstrate that central arterial stiffness, indexed as 
cfPWV, is a predictor of cognitive decline, incident MCI, and CVD in cancer survivorship. 
Importantly, after controlling for age, sex, depressive symptoms, and CVD risk factors, the 
adverse relationships between cfPWV, cognitive decline, and incident CVD persisted. In the 
general population, associations have been previously demonstrated between arterial stiffness 
and cognitive decline (30, 40, 45, 48, 63, 66, 69). As the amount of cancer survivors continues to 
grow, our understanding of the interactions that predispose this community to adverse outcomes 
is vital to the improvement of survivor’s long-term care and quality of life. Our results warrant 
further investigation into the predictive capability of a non-invasive cfPWV assessment of 
central arterial stiffness, with the goal of early identification of patients who are at risk of 
adverse secondary outcomes in clinical practice. 
 
While often viewed as two distinct disease entities, cancer and CVD may coincide due to 
anticancer treatment cardiotoxicities (6, 36) or shared risk factors and biological mechanisms. 
Risk factors shared within cancer and CVD etiologies include obesity, diabetes mellitus, tobacco 
or smoking, diet, dyslipidemia, and hypertension (1, 25, 32, 36, 51). Common pathogenic 
biological mechanisms include a genetic predisposition and systemic signaling involved in 
chronic inflammation and oxidative stress (1, 43). Adding strength to the correlation between 
cancer and CVD is that the onset of one of these diseases potentiates risk of the other. Indeed, 
many forms of CVD are oncogenic including heart failure, hypertension, atrial fibrillation, 
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atherosclerosis, myocardial ischemia or infarction, and stroke (1, 46, 58) and cancer survivors 
are at greater risk of CVD-related mortality than the general public (60).  
 
Evidence linking cancer with increased incidence of CVD has been suggested previously 
in large epidemiological studies. An observational study comparing the US general population to 
over 3 million cancer patients across 28 cancer sites, demonstrated that cancer survivors are at a 
higher risk of CVD related morality than the general population regardless of cancer site and 
time since diagnosis and their risk is greatest in the first year after diagnosis (60). An analysis of 
1.8 million cancer patients demonstrated that heart disease is the leading cause of noncancer 
mortality, with cancer patients at a significantly greater risk of heart disease compared to the 
general population (70). In addition, this increased risk of heart disease in cancer patients is 
independent of the cancer site, time since diagnosis, and age at diagnosis (58, 70). Between 
cancer survivors, the long-term risk of heart disease related mortality, while still elevated 
compared to the general population, is more prevalent according to index-cancer site. Risk 
continually increases following the first year after diagnosis in melanoma, breast, and prostate 
cancers (60) and is greater than that of primary cancer ≥ 10 years post diagnosis in melanoma, 
prostate, colorectal, bladder, kidney, endometrial, oral cavity, and pharynx cancers (58). Our 
study demonstrates that increased cfPWV is predictive of risk of incident CVD during 
survivorship —  consistent with a recent retrospective analysis from our group which was the 
first to establish increased arterial stiffness, assessed via pulse pressure, to be predictive of 
increased CVD mortality in cancer survivors (47).  
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In addition to the shared risk factors and biological mechanisms between these two 
diseases, the use of anticancer therapies may be a significant contributor to the relationship 
between cancer and cardiovascular outcomes. While advancements in anticancer treatment 
regimens have aided in improvement of cancer prognosis, detrimental side effects from these 
drugs potentially promote secondary pathology in survivorship. Work from our group and others 
have demonstrated that vascular toxicities and vascular dysfunction occur following various anti-
cancer treatments (19, 47). Of note, arterial stiffness is a critical vascular toxicity associated with 
cancer treatments in both the short and long-term (27, 57). Anthracyclines, e.g., Doxorubicin, 
represent one of the most widely used classes of chemotherapy drugs (8). In a prospective study 
following survivors receiving anthracycline treatment for a variety of cancer types, a 2-fold 
increase in aortic PWV was documented subsequent to four months of treatment compared to 
pre-treatment measurements, suggesting that aortic stiffness is significantly increased with 
anthracycline therapies (12). Similar findings have resulted from Sunitinib, a tyrosine kinase 
inhibitor, which increased cfPWV and changed other vascular measures related to hemodynamic 
pulsatility following the initial treatment cycle (10). In addition, following treatment with 
alkylating agents, chronic increases in arterial stiffness have been demonstrated (54). FOLOX 
and XELOX, combination therapies using alkylating agent oxaliplatin and antimetabolite 5-
fluorouracil (5FU) or it’s oral prodrug capecitabine, have also been shown to significantly 
increase multiple indices of arterial stiffness (64).  
 
In addition to the above vasculo-toxicity, cognitive deficits during cancer survivorship, 
colloquially referred to as ‘chemofog’ or ‘chemo-brain’, are commonly experienced during 
survivorship. In a 2014 review by Janelsins et al., it is noted that cognitive impairment effects 
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between 17–75% of patients during chemotherapy, and up to 35% of patients years after 
treatment is complete (22). The variability in reported cognitive impairment among patients 
during anticancer treatment often results from the heterogeneity of tests and definitions used to 
define cognitive impairment in this population (49), differences in anticancer therapies and 
patient populations (20), and the multifactorial etiology of these deficits. Interactions between 
trauma associated with receiving a diagnosis, the biology of the neoplasm, and an array of 
treatment-specific, direct or indirect effects of anticancer treatments on cerebral parenchyma or 
vasculature combine to drive cognitive changes throughout the cancer treatment continuum (34, 
42, 49). While research into the precise mechanisms of treatment-mediated neurotoxicity 
continues, concomitant work has been aimed at identifying patients who are most susceptible to 
cognitive decline. To date, commonly identified risk factors for acute cognitive decline include 
age, cognitive reserve, genetic predisposition, and comorbid factors (3, 4, 16, 17, 21, 68). 
Importantly, cognitive changes which are secondary to treatment-mediated toxicity have been 
previously suggested, and include altered cerebrovascular hemodynamics (3). We present 
evidence supporting central arterial stiffness, a known factor contributing to altered 
cerebrovascular hemodynamics, as a risk factor for cognitive change with cancer survivorship.  
 
Chemotherapy has long-term effects on cognitive function. After an average of 21 years 
subsequent to diagnosis, breast cancer survivors who received adjuvant chemotherapy performed 
significantly worse than a cancer-free reference group on tests across multiple cognitive domains 
including immediate and delayed verbal memory, processing speed, executive function, and 
psychomotor speed (26). Chemotherapy-receiving patients may be subject to early onset frailty 
due to acceleration of natural aging processes such as accumulation of DNA damage, 
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accumulation of oxidative stress, shortened telomeres or reduced telomerase activity, and 
neuroendocrine or immunologic dysfunction (11, 21, 35). Demonstrated herein, cfPWV assessed 
an average of 9.1 years after first cancer diagnosis is associated with cognitive decline an 
average of 8.7 years subsequent to cfPWV measurement. In the general population, cfPWV has 
been previously demonstrated to be associated with future cognitive decline and impairment. To 
our knowledge, this is the first study to suggest that cfPWV can significantly predict future 
cognitive decline during cancer survivorship. Further research is needed to understand: 1) what 
role central arterial stiffness plays within the multitude of pathways that contribute to acute and 
long-term cognitive decline and 2) the prevalence of this role in the case that stiffness is present 
prior to treatment or is a result of chemotherapy-induced vascular toxicity.  
 
Our finding that cancer patients with higher cfPWV experienced greater rates of 
cognitive decline may, putatively, be explained by pathophysiologic mechanisms, which drive 
both cancer-mediated and vascular-mediated cognitive change. Both etiologies include 
inflammation, oxidative stress, astrocyte and microglial activation, oligodendrocyte reduction, 
reduced cerebral blood vessel density and blood flow, altered control of cerebral blood flow, and 
white and grey matter damage (14, 15, 20, 34, 42, 49, 53, 59, 61). In addition, greater central 
arterial stiffness, whether due to age or chemotherapy vasculo-toxicity, could beget direct 
chemotherapy-induced neuronal damage. As noted above, cancer treatment mechanisms of 
cognitive change vary between anticancer therapies. With regard to chemotherapy drugs this is 
partially due to the selective permeability of the BBB — the cerebral microvascular interface 
between vasculature and parenchyma (i.e., functional brain tissue) (20). Contained here are 
capillaries tasked with maintaining a homeostatic neural environment and protecting parenchyma 
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from foreign entities (34, 42, 67). Depending upon molecular size or lipophilicity, only specific 
chemotherapeutic agents (e.g. 5FU, methotrexate) are able to cross the BBB, though 
accumulations by larger chemotherapy drugs have also been found in brain parenchyma (34, 42, 
67). Further, direct chemotherapy-mediated neurotoxicity, a proposed etiological component 
(42), may be propagated through chemotherapy-induced pathways which damage the BBB. 
Expression of either inflammatory cytokines or matrix metalloproteinases due to chemotherapy-
induced peripheral inflammation or oxidative stress has been shown to disrupt tight junctions, 
increase BBB permeability, and cause neuronal dysfunction (33, 67). Concordantly, in the 
general population, cerebral microvascular pressure pulsatility subsequent to increased central 
artery stiffness is seen in parallel with increased cerebral inflammatory cytokine expression, 
oxidative stress, matrix metalloproteinase expression, aberrant BBB permeability, and cognitive 
dysfunction (14, 15, 61). When both cancer-mediated and vascular-mediated cognitive change 
etiologies are present, the possibility of overlapping pathways being exacerbated and driving 
increased cognitive decline is noteworthy. Whether disparate cognitive outcomes in 
chemotherapy-receiving patients with higher central artery stiffness may be influenced by 
exacerbated inflammatory or oxidative stress pathways or differences in BBB permeability is 
undetermined. Nevertheless, patients with higher central arterial stiffness have an additional 
known precursor to cerebral microvascular dysfunction and cognitive impairment and, as shown 
in the present study, are associated with greater rates of cognitive decline years into survivorship. 
 
 Experimental considerations 
The present study has strengths and limitations. Strengths include the longitudinal design, 
use of standardized and validated cognitive assessments and empirical MCI cut-off scores, use of 
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the ‘gold-standard’ measure of central arterial stiffness, and heterogenous cancer site 
representation. Limitations include the potential influence of other, unaccounted for, variables. 
Although many potential cofounding variables were controlled for, it is possible that other 
cognitive influences or cardiovascular disease risk factors such as anxiety, cognitive reserve, 
genetic predisposition, diabetes mellitus, fasted blood glucose, diet, or exercise, may have 
affected present findings. Further, the participants were predominantly white, potentially limiting 
generalizability to a diverse group of cancer survivors. Additionally, due to medication data 
unavailability we were unable determine the influences that specific treatments may have had on 
cfPWV measures or cognitive assessments.   
 
 Conclusions 
In closing, we demonstrate that cfPWV is associated with future cognitive decline and 
predictive of incident CVD during cancer survivorship independent of age, sex, depression, and 
CVD risk factors. With less patients now dying of their primary cancer, more patients living 
longer into cancer survivorship, and the proportion of survivors who are older continually 
increasing, early identification of survivors who are most susceptible to detrimental secondary 
outcomes is vital. These findings give important insight to our understanding of secondary 
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